What is Deka Biosciences?
Deka Biosciences, Inc., based in Germantown, Maryland, is a biopharmaceutical company dedicated to developing and delivering transformative medicines for patients battling cancer and inflammatory diseases. The company's focus on addressing critical unmet medical needs positions it as a key player in the competitive life sciences landscape. Its commitment to innovation is reflected in its ongoing research and development efforts aimed at creating novel therapies.
How much funding has Deka Biosciences raised?
Deka Biosciences has raised a total of $40M across 2 funding rounds:
Series A
$20M
Series B
$20M
Series A (2021): $20M with participation from Bayer
Series B (2023): $20M led by Lumira Ventures and MPM BioImpact
Key Investors in Deka Biosciences
Bayer
Bayer is a global life sciences company with significant operations in pharmaceuticals and crop science, known for its commitment to innovation in healthcare and nutrition.
Lumira Ventures
Lumira Ventures is a prominent venture capital firm specializing in investments within the life sciences sector, focusing on early-stage to revenue-generating healthcare innovators.
MPM BioImpact
MPM BioImpact manages venture funds focused on converting scientific breakthroughs into therapeutics, with a mission to reach patients in need.
What's next for Deka Biosciences?
With the recent influx of capital, Deka Biosciences is poised for accelerated growth and the advancement of its therapeutic candidates through clinical development. This strategic financing is expected to fuel further research, expand its operational capabilities, and potentially bring its promising treatments closer to market. The company's trajectory suggests a strong focus on scaling its operations and solidifying its position as a leader in its therapeutic areas.
See full Deka Biosciences company page
